Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma

OBJECTIVES: We wished to evaluate the effects of an antigranulocyte-macrophage colony-stimulating factor monoclonal antibody (KB003) on forced expiratory volume in 1 s (FEV(1)), asthma control and asthma exacerbations in adult asthmatics inadequately controlled by long-acting bronchodilators and inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Molfino, Nestor A, Kuna, Piotr, Leff, Jonathan A, Oh, Chad K, Singh, Dave, Chernow, Marlene, Sutton, Brian, Yarranton, Geoffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Respiratory Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716197/
https://www.ncbi.nlm.nih.gov/pubmed/26739717
http://dx.doi.org/10.1136/bmjopen-2015-007709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716197/
https://www.ncbi.nlm.nih.gov/pubmed/26739717
http://dx.doi.org/10.1136/bmjopen-2015-007709

Ejemplares similares